Bulgaria · Delayed Price · Currency is BGN Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 1.42 billion. The enterprise value is 2.03 billion.
| Market Cap | 1.42B |
| Enterprise Value | 2.03B |
Important Dates
The last earnings date was Sunday, November 30, 2025.
| Earnings Date | Nov 30, 2025 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Sopharma AD has 519.26 million shares outstanding. The number of shares has decreased by -46.99% in one year.
| Current Share Class | 510.90M |
| Shares Outstanding | 519.26M |
| Shares Change (YoY) | -46.99% |
| Shares Change (QoQ) | +3.23% |
| Owned by Insiders (%) | 9.78% |
| Owned by Institutions (%) | 0.42% |
| Float | 126.96M |
Valuation Ratios
The trailing PE ratio is 6.18.
| PE Ratio | 6.18 |
| Forward PE | n/a |
| PS Ratio | 0.56 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 76.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.77, with an EV/FCF ratio of -84.51.
| EV / Earnings | 16.31 |
| EV / Sales | 0.81 |
| EV / EBITDA | 8.77 |
| EV / EBIT | 12.30 |
| EV / FCF | -84.51 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.31 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 3.24 |
| Debt / FCF | -26.40 |
| Interest Coverage | 6.22 |
Financial Efficiency
Return on equity (ROE) is 14.42% and return on invested capital (ROIC) is 5.26%.
| Return on Equity (ROE) | 14.42% |
| Return on Assets (ROA) | 4.19% |
| Return on Invested Capital (ROIC) | 5.26% |
| Return on Capital Employed (ROCE) | 9.83% |
| Revenue Per Employee | 425,886 |
| Profits Per Employee | 21,066 |
| Employee Count | 5,599 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 4.34 |
Taxes
In the past 12 months, Sopharma AD has paid 17.27 million in taxes.
| Income Tax | 17.27M |
| Effective Tax Rate | 11.62% |
Stock Price Statistics
The stock price has increased by +43.68% in the last 52 weeks. The beta is -0.09, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | +43.68% |
| 50-Day Moving Average | 2.70 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 58.19 |
| Average Volume (20 Days) | 41,943 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.51 billion and earned 124.18 million in profits. Earnings per share was 0.44.
| Revenue | 2.51B |
| Gross Profit | 575.92M |
| Operating Income | 120.60M |
| Pretax Income | 148.72M |
| Net Income | 124.18M |
| EBITDA | 174.36M |
| EBIT | 120.60M |
| Earnings Per Share (EPS) | 0.44 |
Balance Sheet
The company has 32.65 million in cash and 632.91 million in debt, giving a net cash position of -600.26 million or -1.16 per share.
| Cash & Cash Equivalents | 32.65M |
| Total Debt | 632.91M |
| Net Cash | -600.26M |
| Net Cash Per Share | -1.16 |
| Equity (Book Value) | 981.36M |
| Book Value Per Share | 1.84 |
| Working Capital | 245.60M |
Cash Flow
In the last 12 months, operating cash flow was 18.49 million and capital expenditures -42.46 million, giving a free cash flow of -23.97 million.
| Operating Cash Flow | 18.49M |
| Capital Expenditures | -42.46M |
| Free Cash Flow | -23.97M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 22.94%, with operating and profit margins of 4.80% and 4.95%.
| Gross Margin | 22.94% |
| Operating Margin | 4.80% |
| Pretax Margin | 5.92% |
| Profit Margin | 4.95% |
| EBITDA Margin | 6.94% |
| EBIT Margin | 4.80% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 1.89%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 1.89% |
| Dividend Growth (YoY) | -68.18% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.91% |
| Buyback Yield | 46.99% |
| Shareholder Yield | 48.89% |
| Earnings Yield | 8.76% |
| FCF Yield | -1.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.49 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.49 |
| Piotroski F-Score | 5 |